{"denoms":[{"counts":[{"groupId":"BG000","value":"64"}],"units":"Participants"}],"groups":[{"description":"Patients must have no nausea and/or vomiting for 24 hours and must not have used other anti-emetics for 72 hours prior to starting protocol treatment. Treatment must not start until this criteria is satisfied.\n\n\\- Any germ cell chemotherapy regimen utilizing Cisplatin (20mg/m\\^2 x 5 days).\n\nAcute emesis prophylaxis:\n\n* Any 5HT3 receptor antagonist may be used D1 - 5 or D1, 3 and 5 if palonosetron is used per institutional standards.\n* Dexamethasone 20mg PO (orally) daily, D1 and 2\n* Fosaprepitant 150mg IV on day 3\n\nDelayed emesis prophylaxis:\n\n* Fosaprepitant 150mg IV on D5\n* Dexamethasone 4mg PO BID (twice a day) on D6, 7 and 8\n\nPRN antiemetics allowed at the discretion of the treating investigator\n\n* No additional doses of 5HT3 receptor antagonist, dexamethasone, or fosaprepitant will be given during the acute or delayed treatment periods\n\nFosaprepitant: Fosaprepitant 150mg IV D3 for acute prophylaxis Fosaprepitant 150mg IV on Day 5 for delayed prophyl","id":"BG000","title":"Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"15","upperLimit":"66","value":"33"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"64"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"61"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"64"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59"}]}],"title":"ECOG PS 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"ECOG PS 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"ECOG PS 2"}],"description":"Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) from 0-5 that describes a patient's level of functioning where 0=Fully active, able to carry on all pre-disease performance without restriction and 5=Dead:","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) performance status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27"}]}],"title":"Cancer Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"24"}]}],"title":"Cancer Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"Cancer Stage III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Cancer Stage IS"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Cancer Stage Unknown"}],"description":"Stage 0 Abnormal cells are present but have not spread to nearby tissue. Also called carcinoma in situ, or CIS. CIS is not cancer, but it may become cancer.\n\nStage I, Stage II, and Stage III Cancer is present. The higher the number, the larger the cancer tumor and the more it has spread into nearby tissues.\n\nStage IV The cancer has spread to distant parts of the body.","paramType":"NUMBER","title":"Cancer Stage","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Participants with Prior Chemotherapy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"59"}]}],"title":"Participants without Prior Chemotherapy"}],"paramType":"NUMBER","title":"Prior Chemotherapy","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"51"}]}],"title":"Bleomycin, etoposide, cisplatin"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"Etoposide, cisplatin"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Vinblastine, ifosfamide, cisplatin"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Cisplatin, Epirubicin"}],"paramType":"NUMBER","title":"Chemotherapy Regimen","unitOfMeasure":"participants"}],"populationDescription":"64 participants were consented and treated per protocol. 1 participant listed in participant flow experienced an adverse event during infusion and was immediately taken off study. His baseline characteristics are not included in this table."}